Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
USA Today: Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability
press clippings
USA Today: Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes’ Technology and ScalabilityMarch 20, 2026
GEN: eXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical
press clippings
GEN: eXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman ChemicalMarch 19, 2026
eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade output
investornutraceuticalsmedicine
EXOZ investor update: eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade outputMarch 18, 2026
Video interview: Cayman Chemical validates eXoZymes' technology and scalability
press releasenutraceuticalsmedicinevideo
Video interview: Successful pilot scale run with Cayman Chemical validates eXoZymes' technology and scalabilityMarch 18, 2026
2026 MISTA Symposium Healthspan
press releasenutraceuticalsmedicine
eXoZymes’ CCO Damien Perriman to Present a NCT solution at next week’s MISTA SymposiumMarch 12, 2026
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026
investorpress clippingsvideo
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026February 16, 2026
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creation
press releaseinvestor
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creationFebruary 10, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
yahoo! finance
investorpress clippings
yahoo! finance: eXoZymes demonstrates end-to-end biomanufacturability of NCT, from reaction to high-purity isolated productJanuary 30, 2026
Pharma-grade NCT ready for partner testing
press releaseinvestornutraceuticalsscience
eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot runJanuary 29, 2026
Previous page
Page 2 of 12
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark